Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Terminated 3Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2

Conditions

Multiple Myeloma 2Waldenstrom Macroglobulinemia 1Lymphoma, T-Cell, Peripheral 1

Interventions

Magnetic Resonance Spectroscopy 262Specimen Handling 253pembrolizumab 230Cyclophosphamide 216Radiotherapy 204Nivolumab 168Cisplatin 161Carboplatin 145Biopsy 144Radiosurgery 128fludarabine 123Blood Specimen Collection 116Gemcitabine 111Paclitaxel 107Surveys and Questionnaires 106Standard of Care 102venetoclax 94Dexamethasone 93Bevacizumab 92Radiation 87Rituximab 81Capecitabine 80Cytarabine 79Oxaliplatin 77Drug Therapy 75Doxorubicin 75Ipilimumab 73durvalumab 70fludarabine phosphate 69atezolizumab 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × ixazomib × 90 days × Clear all
NCT03757221 2026-05-13

IDARA

University Hospital, Caen

Phase 2 Terminated
55 enrolled
Plasma cell

Multiple Myeloma

NCT03547700 2026-05-06

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

University of Michigan Rogel Cancer Center

Phase 1/2 Terminated
11 enrolled 10 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03506373 2026-05-05

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Mayo Clinic

Phase 2 Terminated
21 enrolled 11 charts
Lymphoid

Waldenstrom Macroglobulinemia

NCT03763162 2026-04-15

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
40 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡